1. The present study was undertaken to investigate the possibility that central nervous system mono-aminergic pathways may play a role in the control of the renin-angiotensinaldosterone system in man.
Introduction
It is well known that the central nervous system plays a major role in the control of renin and aldosterone secretion. The release of renin is augmented by medullary [I], pontine [2] , mesencephalic [3l and hypothalamic defence area [41 stimulation, while activation of the so-called sympatho-inhibitory area in the anterior hypothalamus decreases renin secretion [ 51.
These changes are believed to be mediated by the renal sympathetic nerves, since they are abolished by renal denervation. The present study was undertaken to evaluate whether a change in central nervous system catecholamines may affect plasma renin activity (PRA) and plasma aldosterone levels in man.
Patients and methods
Eight healthy subjects (five females aged 24-28 years, three males aged 25-27 years) with normal blood pressure and no evidence of renal, gastrointestinal or endocrine disorders, volunteered for the study. Informed consent was obtained from all individuals. The subjects were put on a constant daily diet containing 130 mmol of sodium, 60 mmol of potassium, 1 g of protein/kg and 2500 cal (10.46 kJ), for 5 days before the studies. On day 5, a 24 h urine sample was collected and analysed for sodium and potassium.
Subjects fasted overnight and were in the supine position in a quiet room throughout the study and for 90 min preceding it. Arterial blood pressure was then measured and blood samples were drawn through an indwelling catheter inserted into an antecubital vein, at -30 and 0 min, as basal values. To maintain the patency of the cannula, 150 ml of glucose solution (0.28 mol/l, 5 g/100 ml) was infused during the studies. All subjects were given in a randomized order, at a 2 day interval, placebo, L-dopa (500 mg, orally) and L-dopa (100 mg, orally) plus carbidopa (35 mg, orally), after pretreatment with carbidopa (50 mg, orally every 6 h for four doses). Blood pressure was determined and blood samples were collected at the time intervals indicated in Fig. 1 . All blood samples for PRA and plasma aldosterone determinations were collected in chilled glass tubes, with ethylenediaminetetraacetate (EDTA) as anticoagulant, centrifuged immediately and plasmas were separated and frozen until the assays, which were performed within 2 weeks after collections. PRA was determined by radioimmunoassay of angiotensin I generated, as described by Haber, Koerner, Page, Kliman & Purnode [61; plasma aldosterone was measured by the radioimmunoassay method of Vetter, Vetter & Siegenthaler [71. In our laboratory the interassay variation is 9% for PRA and 8% for plasma aldosterone, while the intra-assay variation is 6% for both PRA and plasma aldosterone. Each plasma was assayed in triplicate. Serum and urinary sodium and potassium were measured by flame photometry (Corning model 450). Plasma cortisol was determined as described by Mattingly [81. Blood pressure was measured with a mercury sphygmomanometer, the point of muffling of sounds being taken as diastolic pressure.
The statistical assessment of data was performed by trend analysis and analysis of variance followed by Tukey's t-test for multiple comparisons. P values of < 0.05 were considered significant. Data are means SEM.
Results
The results of the present study are outlined in Fig. 1 .
The subjects were in sodium and potassium balance, as indicated by the 24 h urinary sodium and potassium excretion, which closely matched intakes. Trend analysis revealed no significant changes in arterial blood pressure as well as in PRA and plasma aldosterone levels, after placebo.
L-Dopa administration elicited a significant fall in PRA (P < 0-01 at 120, 150 and 180 min) and in plasma aldosterone concentration (P < 0.05 from 90 to 180 min) versus placebo study, without significant changes in blood pressure, plasma cortisol or serum electrolytes; the nadir values of PRA and plasma aldosterone were 4 1 a9 f-4.1 and 53.9 f 7.1% of the basal levels respectively. L-Dopa plus carbidopa induced a decrease in PRA ( P < 0.02 at 120 and 150 min, P < 0.01 at 180 min) and in plasma aldosterone levels ( P < 0.02 at 30 and 60 min, P < 0.01 at 90 and 120 min), in comparison with placebo administration; the nadir values of PRA and plasma aldosterone were 44.3 & 7.3 and 52.4 f-9.4% of basal; no changes were observed in blood pressure. The between-drugs analysis revealed that decreases in PRA and plasma aldosterone after L-dopa alone and after L-dopa plus carbidopa were not significantly different.
Discussion
In the present study L-dopa administration with and without inhibition of extracerebral dopa decarboxylase reduced PRA in healthy individuals, in general agreement with the findings by Barbeau, Gillo-Joffroy, Boucher, Nowaczynski & Genest [91 who showed a decreased PRA in Parkinsonian patients chronically treated with high doses of L-dopa. Systemic administration of L-dopa is followed by its conversion into catecholamines not only within the central nervous system, but also in peripheral nerve terminals. This raises the possibility that some effects of systemically administered L-dopa may be due to a peripheral activity. When the conversion of L-dopa into dopamine outside the central nervous system is prevented, it is possible to discriminate between centrally and peripherally mediated L-dopa effects. Carbidopa is an agent which in a limited dose range does not cross the blood-brain barrier [ 101 and therefore inhibits extracerebral but not cerebral dopa decarboxylase activity [ill.
The present data indicate that the observed decrease in PRA depends on a centrally mediated L-dopa effect. It has been previously observed in animal models that L-dopa, as well as L-dopa plus carbidopa administration, augments catecholamine levels in the brain [12, 131. However, the neurotransmitter system activated in the central nervous system remains to be elucidated, since augmented brain L-dopa levels Although the mechanism in man mediating the reduction of PRA after L-dopa as well as L-dopa plus carbidopa is not clarified, it is likely that these treatments increase central nervous system catecholamine levels with a resulting decrease in sympathetic activity in the renal nerves and inhibition in PRA. The present findings also show that L-dopa, both alone and in combination with carbidopa, induces a fall in plasma aldosterone levels. The mechanism(s) mediating this effect are not clear. The difference in the time course of the changes in PRA and plasma aldosterone suggests that decreased renin secretion does not have a major role in reducing plasma aldosterone levels under the experimental conditions, although the low PRA might contribute to the effect on plasma aldosterone at later sampling times. The other major factors regulating aldosterone secretion do not seem to be involved in L-dopa-induced aldosterone inhibition, since plasma cortisol and serum sodium and potassium concentrations were not modified by L-dopa. It has been proposed that the dopaminergic system may exert an inhibitory control on aldosterone secretion [ , are involved in the inhibition of aldosterone release observed in the present study, inasmuch as they do not seem to be implicated in the control of aldosterone secretion in man 122-251. In conclusion, the present data suggest that the observed inhibition of plasma aldosterone levels after L-dopa, with and without carbidopa, may depend on a central dopaminergic stimulation.
